Compare Home Depot Inc (HD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Home Depot Inc trades at $345.58 (market cap $353.46B), while State Street SPDR S&P Biotech ETF trades at $159.05. The key difference: Home Depot Inc pays a 2.63% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Home Depot Inc nearer its low. Which is the better fit depends on your goals.
| HD | XBI | |
|---|---|---|
Market Cap | $353.46B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $423.42 | $164.28 |
52-Week Low | $297.51 | $86.92 |
Enterprise Value | $415.01B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $350.78, down 1.36% on the day, with a bullish technical outlook supported by moving averages. The company reported mixed quarterly earnings, missing in Q3 2025 but beating in Q4 2025 and Q1 2026. Strong profitability metrics include a 33.13% gross margin and 128.38% ROE, though net margins have declined from 10.87% in 2022 to 8.41% in 2026. Recent news highlights institutional trading activity and concerns about weakening big-ticket demand amid rising mortgage rates.
The stock offers a 6% upside to the consensus price target of $371.25, with 59% of analysts rating it Buy. Key risks include housing market sensitivity and margin pressure from investments. Long-term growth drivers include Pro customer focus and digital expansion, but near-term headwinds from economic conditions warrant caution.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
